{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:01Z","timestamp":1793262001448,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic condition characterized by high levels of Low density lipoprotein cholesterol (LDL-C); overt, early-onset atherosclerotic cardiovascular disease (ASCVD); and premature cardiovascular events and mortality. Lomitapide is a first-in-class microsomal triglyceride transfer protein inhibitor for the treatment of HoFH. This review provides an update on data emerging from real-world studies of lomitapide following on from its pivotal phase 3 clinical trial in HoFH.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>Recent registry data have confirmed that HoFH is characterized by delayed diagnosis, with many patients not receiving effective therapy until they are approaching the age when major adverse cardiovascular events may occur. Data from case series of varying sizes, and from a 163-patient registry of HoFH patients receiving lomitapide, have demonstrated that lomitapide doses are lower and adverse events less severe than in the phase 3 study. Lomitapide enables many patients to reach European Atherosclerosis Society LDL-C targets. Some patients are able to reduce frequency of lipoprotein apheresis or, in some cases, stop the procedure altogether\u2014unless there is significant elevation of lipoprotein (a). Modelling analyses based on historical and clinical trial data indicate that lomitapide has the potential to improve cardiovascular outcomes and survival in HoFH.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>Real-world clinical experience with lomitapide has shown the drug to be effective with manageable, less marked adverse events than in formal clinical studies. Event modelling data suggest a survival benefit with lomitapide in HoFH.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11883-020-00858-4","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T09:02:36Z","timestamp":1592470956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Lomitapide\u2013a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia"],"prefix":"10.1007","volume":"22","author":[{"given":"Claudia","family":"Stefanutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"issue":"32","key":"858_CR1","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274.","journal-title":"Eur Heart J"},{"key":"858_CR2","doi-asserted-by":"publisher","unstructured":"Representatives of the Global Familial Hypercholesterolemia C, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. 2020. doi:https:\/\/doi.org\/10.1001\/jamacardio.2019.5173.","DOI":"10.1001\/jamacardio.2019.5173"},{"issue":"45","key":"858_CR3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J"},{"issue":"3","key":"858_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","volume":"36","author":"B Sjouke","year":"2015","unstructured":"Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36(3):560\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/ehu058.","journal-title":"Eur Heart J"},{"issue":"6","key":"858_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2174\/1570161113666150827125040","volume":"13","author":"A Al-Ashwal","year":"2015","unstructured":"Al-Ashwal A, Alnouri F, Sabbour H, Al-Mahfouz A, Al-Sayed N, Razzaghy-Azar M, et al. Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East Advisory Panel. Curr Vasc Pharmacol. 2015;13(6):759\u201370.","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"858_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.02.019.","journal-title":"Atherosclerosis."},{"key":"858_CR7","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.atherosclerosis.2018.06.221","volume":"275","author":"M Hartgers","year":"2018","unstructured":"\u2022 Hartgers M, Cuchel M, Hovingh GK, Blom DJ, Raal FJ. Clinical, demographic and genetic characteristics of homozygous familial hypercholesterolemia patients worldwide: Interim results from the hofh international clinical collaborators (HICC) registry. Atherosclerosis. 2018;275:e80. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.221Recent international registry data on HoFH.","journal-title":"Atherosclerosis"},{"key":"858_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2018.01.034","volume":"270","author":"M Kayikcioglu","year":"2018","unstructured":"\u2022 Kayikcioglu M, Tokgozoglu L, Yilmaz M, Kaynar L, Aktan M, Durmus RB, et al. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis. 2018;270:42\u20138. Turkish HoFH registry data of patients on LA. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.01.034.","journal-title":"Atherosclerosis"},{"issue":"4","key":"858_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","volume":"5","author":"C Stancu","year":"2001","unstructured":"Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378\u201387. https:\/\/doi.org\/10.1111\/j.1582-4934.2001.tb00172.x.","journal-title":"J Cell Mol Med"},{"issue":"12","key":"858_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","volume":"76","author":"S Krahenbuhl","year":"2016","unstructured":"Krahenbuhl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won\u2019t do! Drugs. 2016;76(12):1175\u201390. https:\/\/doi.org\/10.1007\/s40265-016-0613-0.","journal-title":"Drugs."},{"issue":"9","key":"858_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","volume":"102","author":"LC Hudgins","year":"2008","unstructured":"Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(9):1199\u2013204. https:\/\/doi.org\/10.1016\/j.amjcard.2008.06.049.","journal-title":"Am J Cardiol"},{"issue":"1","key":"858_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","volume":"17","author":"C Stefanutti","year":"2015","unstructured":"Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015;17(1):465. https:\/\/doi.org\/10.1007\/s11883-014-0465-6.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"858_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","volume":"208","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2):317\u201321. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.06.010.","journal-title":"Atherosclerosis."},{"issue":"2","key":"858_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","volume":"152","author":"AA Kroon","year":"2000","unstructured":"Kroon AA, van\u2019t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519\u201326. https:\/\/doi.org\/10.1016\/S0021-9150(00)00371-3.","journal-title":"Atherosclerosis."},{"issue":"6","key":"858_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","volume":"21","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21(6):492\u20138. https:\/\/doi.org\/10.1097\/MOL.0b013e3283402f53.","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"858_CR16","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1007\/s12325-019-00985-8","volume":"36","author":"T Ben-Omran","year":"2019","unstructured":"Ben-Omran T, Masana L, Kolovou G, Ariceta G, Novoa FJ, Lund AM, et al. Real-world outcomes with Lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786\u2013811. https:\/\/doi.org\/10.1007\/s12325-019-00985-8.","journal-title":"Adv Ther"},{"key":"858_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.atherosclerosissup.2014.07.006","volume":"15","author":"E Bruckert","year":"2014","unstructured":"Bruckert E, Saheb S, Bont\u00e9 JR, Coudray-Omn\u00e8s C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey. Atheroscler Suppl. 2014;15:46\u201351.","journal-title":"Atheroscler Suppl"},{"issue":"4","key":"858_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacl.2019.05.002","volume":"13","author":"C Stefanutti","year":"2019","unstructured":"\u2022\u2022 Stefanutti C, Pang J, Di Giacomo S, Wu X, Wang X, Morozzi C, et al. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman Study. Journal of Clinical Lipidology. 2019;13(4):608\u201317. https:\/\/doi.org\/10.1016\/j.jacl.2019.05.002A key report that uses differences in regional HoFH management practices to determine how to improve survival in HoFH.","journal-title":"Journal of Clinical Lipidology"},{"issue":"3","key":"858_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cyto.2011.08.027","volume":"56","author":"C Stefanutti","year":"2011","unstructured":"Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine. 2011;56(3):842\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2011.08.027.","journal-title":"Cytokine."},{"issue":"7","key":"858_CR20","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/s0735-1097(96)00388-9","volume":"28","author":"WR Aengevaeren","year":"1996","unstructured":"Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJ, van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol. 1996;28(7):1696\u2013704. https:\/\/doi.org\/10.1016\/s0735-1097(96)00388-9.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"858_CR21","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.1073\/pnas.0904560106","volume":"106","author":"D Steinberg","year":"2009","unstructured":"Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009;106(24):9546\u20137. https:\/\/doi.org\/10.1073\/pnas.0904560106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9965","key":"858_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(14)61374-X.","journal-title":"Lancet."},{"key":"858_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5:280\u201390. https:\/\/doi.org\/10.1016\/S2213-8587(17)30044-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"858_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","volume":"75","author":"RD Santos","year":"2020","unstructured":"Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(6):565\u201374. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.020.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"858_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/ATVBAHA.117.310675","volume":"38","author":"RD Santos","year":"2018","unstructured":"Santos RD. Expression of LDLRs (low-density lipoprotein receptors), dyslipidemia severity, and response to PCSK9 (proprotein convertase subtilisin kexin type 9) inhibition in homozygous familial hypercholesterolemia: connecting the dots. Arterioscler Thromb Vasc Biol. 2018;38(3):481\u20133. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310675.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"858_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S2213-8587(17)30060-8","volume":"5","author":"G Thompson","year":"2017","unstructured":"Thompson G. Limitations of cholesterol lowering with PCSK9 inhibitors. Lancet Diabetes Endocrinol. 2017;5(4):241\u20133. https:\/\/doi.org\/10.1016\/S2213-8587(17)30060-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"858_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001292.","journal-title":"Circulation."},{"issue":"2","key":"858_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa061189","volume":"356","author":"M Cuchel","year":"2007","unstructured":"Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148\u201356. https:\/\/doi.org\/10.1056\/NEJMoa061189.","journal-title":"N Engl J Med"},{"issue":"3","key":"858_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00041433-199706000-00002","volume":"8","author":"DA Gordon","year":"1997","unstructured":"Gordon DA. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Curr Opin Lipidol. 1997;8(3):131\u20137. https:\/\/doi.org\/10.1097\/00041433-199706000-00002.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"858_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","volume":"25","author":"FK Welty","year":"2014","unstructured":"Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol. 2014;25(3):161\u20138. https:\/\/doi.org\/10.1097\/MOL.0000000000000072.","journal-title":"Curr Opin Lipidol"},{"issue":"9860","key":"858_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(12)61731-0.","journal-title":"Lancet."},{"issue":"3","key":"858_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","volume":"136","author":"DJ Blom","year":"2017","unstructured":"Blom DJ, Averna MR, Meagher EA, du Toit TH, Sirtori CR, Hegele RA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor Lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136(3):332\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028208.","journal-title":"Circulation."},{"issue":"4","key":"858_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5551\/jat.38216","volume":"24","author":"M Harada-Shiba","year":"2017","unstructured":"Harada-Shiba M, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, et al. Efficacy and safety of Lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2017;24(4):402\u201311. https:\/\/doi.org\/10.5551\/jat.38216.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"858_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5551\/jat.45708","volume":"26","author":"A Nohara","year":"2019","unstructured":"Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study. J Atheroscler Thromb. 2019;26(4):368\u201377. https:\/\/doi.org\/10.5551\/jat.45708.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"858_CR35","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","volume":"11","author":"C Stefanutti","year":"2017","unstructured":"Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, Schettler VJ, et al. Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of clinical lipidology. 2017;11(4):858\u201371 e3. https:\/\/doi.org\/10.1016\/j.jacl.2017.04.114.","journal-title":"Journal of clinical lipidology."},{"issue":"5","key":"858_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","volume":"34","author":"L D\u2019Erasmo","year":"2017","unstructured":"D\u2019Erasmo L, Cefalu AB, Noto D, Giammanco A, Averna M, Pintus P, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther. 2017;34(5):1200\u201310. https:\/\/doi.org\/10.1007\/s12325-017-0531-x.","journal-title":"Adv Ther"},{"key":"858_CR37","doi-asserted-by":"publisher","unstructured":"D\u2019Erasmo L, Minicocci I, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L et al. Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes. J Am Coll Cardiol 2018;71(3):279\u2013288. doi:https:\/\/doi.org\/10.1016\/j.jacc.2017.11.028.","DOI":"10.1016\/j.jacc.2017.11.028"},{"issue":"5520","key":"858_CR38","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1126\/science.1060458","volume":"292","author":"CK Garcia","year":"2001","unstructured":"Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292(5520):1394\u20138. https:\/\/doi.org\/10.1126\/science.1060458.","journal-title":"Science."},{"issue":"49","key":"858_CR39","doi-asserted-by":"publisher","first-page":"40996","DOI":"10.1074\/jbc.M509394200","volume":"280","author":"R Garuti","year":"2005","unstructured":"Garuti R, Jones C, Li WP, Michaely P, Herz J, Gerard RD, et al. The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem. 2005;280(49):40996\u20131004. https:\/\/doi.org\/10.1074\/jbc.M509394200.","journal-title":"J Biol Chem"},{"key":"858_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.12.006","volume":"269","author":"RM Sanchez-Hernandez","year":"2018","unstructured":"Sanchez-Hernandez RM, Prieto-Matos P, Civeira F, Lafuente EE, Vargas MF, Real JT, et al. Autosomal recessive hypercholesterolemia in Spain. Atherosclerosis. 2018;269:1\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.006.","journal-title":"Atherosclerosis."},{"issue":"4","key":"858_CR41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jacl.2016.02.009","volume":"10","author":"C Stefanutti","year":"2016","unstructured":"Stefanutti C, Morozzi C, Di Giacomo S, Sovrano B, Mesce D, Grossi A. Management of homozygous familial hypercholesterolemia in real-world clinical practice: a report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. Journal of clinical lipidology. 2016;10(4):782\u20139. https:\/\/doi.org\/10.1016\/j.jacl.2016.02.009.","journal-title":"Journal of clinical lipidology."},{"issue":"3","key":"858_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2459\/JCM.0000000000000620","volume":"19","author":"S Sperlongano","year":"2018","unstructured":"Sperlongano S, Gragnano F, Natale F, D\u2019Erasmo L, Concilio C, Cesaro A, et al. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. J Cardiovasc Med (Hagerstown). 2018;19(3):83\u201390. https:\/\/doi.org\/10.2459\/JCM.0000000000000620.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"858_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacl.2015.05.001","volume":"9","author":"J Roeters van Lennep","year":"2015","unstructured":"Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide. Journal of clinical lipidology. 2015;9(4):607\u201317. https:\/\/doi.org\/10.1016\/j.jacl.2015.05.001.","journal-title":"Journal of clinical lipidology."},{"issue":"2","key":"858_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/2047487319870007","volume":"27","author":"G Kolovou","year":"2020","unstructured":"Kolovou G, Diakoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2020;27(2):157\u201365. https:\/\/doi.org\/10.1177\/2047487319870007.","journal-title":"Eur J Prev Cardiol"},{"key":"858_CR45","doi-asserted-by":"publisher","unstructured":"\u2022 Real J, Arbona C, Goterris R, Ascaso JF. Management of homozygous familial hypercholesterolaemia in two brothers. BMJ Case Rep. 2018;2018. https:\/\/doi.org\/10.1136\/bcr-2017-222155An interesting case series that highlights the heterogeneity of management in HoFH.","DOI":"10.1136\/bcr-2017-222155"},{"key":"858_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/CE.S174169","volume":"14","author":"R Alonso","year":"2019","unstructured":"Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019;14:19\u201330. https:\/\/doi.org\/10.2147\/CE.S174169.","journal-title":"Core Evid"},{"issue":"7","key":"858_CR47","doi-asserted-by":"publisher","first-page":"878","DOI":"10.5551\/jat.34777","volume":"23","author":"GD Kolovou","year":"2016","unstructured":"Kolovou GD, Kolovou V, Papadopoulou A, Watts GF. MTP gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2016;23(7):878\u201383. https:\/\/doi.org\/10.5551\/jat.34777.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"858_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jacl.2014.08.005","volume":"9","author":"A Raper","year":"2015","unstructured":"Raper A, Kolansky DM, Sachais BS, Meagher EA, Baer AL, Cuchel M. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. Journal of clinical lipidology. 2015;9(1):107\u201312. https:\/\/doi.org\/10.1016\/j.jacl.2014.08.005.","journal-title":"Journal of clinical lipidology."},{"issue":"3","key":"858_CR49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jacl.2019.03.001","volume":"13","author":"APM Chacra","year":"2019","unstructured":"Chacra APM, Ferrari MC, Rocha VZ, Santos RD. Case report: the efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Journal of clinical lipidology. 2019;13(3):397\u2013401. https:\/\/doi.org\/10.1016\/j.jacl.2019.03.001.","journal-title":"Journal of clinical lipidology"},{"issue":"3","key":"858_CR50","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccas.2019.06.029","volume":"1","author":"G Kolovou","year":"2019","unstructured":"Kolovou G, Tsoutsinos A, Mastorakou I, Mavrogeni S, Hatzigeorgiou G. Xanthomas regression in an 8-year-old boy treated with lomitapide. JACC Case Reports. 2019;1(3):414\u20136. https:\/\/doi.org\/10.1016\/j.jaccas.2019.06.029.","journal-title":"JACC Case Reports"},{"issue":"Suppl. 1","key":"858_CR51","doi-asserted-by":"publisher","first-page":"S588","DOI":"10.1016\/S0168-8278(18)31438-7","volume":"68","author":"D Larrey","year":"2018","unstructured":"\u2022\u2022 Larrey D, Underberg J, Cannon C, Makris L, Jurecka A, Blom D. Long-term liver safety of lomitapide in patients with homozygous familial hypercholesterolemia: three-year data from the lomitapide observational worldwide evaluation registry (LOWER). J Hepatol. 2018;68(Suppl. 1):S588 The most recent published dataset from the long-term lomitapide registry.","journal-title":"J Hepatol"},{"key":"858_CR52","unstructured":"Amryt Pharmaceuticals DAC. Lojuxta summary of product characteristics. 2017."},{"issue":"17","key":"858_CR53","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/2047487317730473","volume":"24","author":"R Leipold","year":"2017","unstructured":"Leipold R, Raal F, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis. Eur J Prev Cardiol. 2017;24(17):1843\u201350. https:\/\/doi.org\/10.1177\/2047487317730473.","journal-title":"Eur J Prev Cardiol"},{"issue":"20","key":"858_CR54","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","volume":"124","author":"FJ Raal","year":"2011","unstructured":"Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.042523.","journal-title":"Circulation."},{"issue":"1","key":"858_CR55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13023-018-0841-3","volume":"13","author":"DJ Blom","year":"2018","unstructured":"Blom DJ, Cuchel M, Ager M, Phillips H. Target achievement and cardiovascular event rates with Lomitapide in homozygous familial hypercholesterolaemia. Orphanet J Rare Dis. 2018;13(1):96. https:\/\/doi.org\/10.1186\/s13023-018-0841-3.","journal-title":"Orphanet J Rare Dis"}],"updated-by":[{"DOI":"10.1007\/s11883-020-00869-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000}}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00858-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:25:09Z","timestamp":1623975909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00858-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00858-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"18 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Due to errors during galley proofing, the original version of this article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and Ethical Standards"}},{"value":"Professor Stefanutti has no current, relevant conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"38"}}